Skip to main content

Eli Lilly Business Team Staffer to Head SYN X s Development Efforts

NEW YORK, March 12 – Aaron Davidson, previously a member of Eli Lilly’s corporate development team, has been named vice president of business development at SYN X Pharma, the company said Monday.

SYN X, a Toronto-based proteomics company is looking to launch deals for therapeutics and diagnostics stemming from the company’s initiatives.

During his nine-year tenure with Eli Lilly, Davidson completed a number of multi-million dollar in- licensing, out-partnering, and distribution deals in the areas of epilepsy, Parkinson's disease, and oncology. 

At SYN X Davidson will be responsible for developing and accelerating strategic alliances for the company’s Proteomics Discovery Platform, which can be used to identify protein targets for the development of new drugs and antibody-based diagnostics. 

The company is currently developing diagnostics for diabetes, cardiovascular and central nervous system diseases.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.